Media headlines about Aerie Pharmaceuticals (NASDAQ:AERI) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.1514308758338 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Aerie Pharmaceuticals (AERI) Upgraded to Hold at BidaskClub (americanbankingnews.com)
- Stock of Aerie Pharmaceuticals, Inc. (AERI) moves 45.79% away from One Year Low – Nasdaq Chronicle (nasdaqchronicle.com)
- Aerie Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference (wallstreet-online.de)
- Brief Overview on Stock’s Performances – Aerie Pharmaceuticals Inc (NASDAQ: AERI) – Stocks Pen (stockspen.com)
- Aerie Pharmaceuticals to Present at the 17 – Business Wire (press release) (businesswire.com)
Aerie Pharmaceuticals (NASDAQ:AERI) opened at $53.05 on Monday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 10.09 and a current ratio of 10.09. The company has a market capitalization of $2,095.10, a P/E ratio of -13.03 and a beta of 0.98. Aerie Pharmaceuticals has a twelve month low of $38.14 and a twelve month high of $66.60.
A number of analysts have recently weighed in on AERI shares. BidaskClub raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Cantor Fitzgerald set a $77.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 18th. Canaccord Genuity set a $73.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 18th. Mizuho restated a “buy” rating and set a $87.00 target price on shares of Aerie Pharmaceuticals in a report on Tuesday, December 19th. Finally, Zacks Investment Research upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, January 22nd. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Aerie Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $78.75.
ILLEGAL ACTIVITY WARNING: This piece was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3301092/aerie-pharmaceuticals-aeri-getting-somewhat-favorable-news-coverage-analysis-finds.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.